Lipella Pharmaceuticals Inc. (LIPO) Return on equity 2021–2024
Lipella Pharmaceuticals Inc. (LIPO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-261.3%FY2024 · since FY2021: -131.0% → -261.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -261.3% | -114.4 pp |
| FY2023 | -146.9% | -91.3 pp |
| FY2022 | -55.6% | +75.5 pp |
| FY2021 | -131.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More LIPO financial trends
LIPO RevenueLIPO Net incomeLIPO Net marginLIPO Gross profitLIPO Gross marginLIPO Operating incomeLIPO Operating marginLIPO Operating cash flowLIPO Free cash flowLIPO Capital expendituresLIPO Stock buybacksLIPO Dividends paidLIPO Total assetsLIPO Total liabilitiesLIPO Shareholders’ equityLIPO overview →